For instance, TRIM21 has been demonstrated to be downregulated in hepatocellular carcinoma, breast cancer, and diffuse large B-cell lymphomas10–13, whereas other studies have shown that decreased expression of TRIM21 predicts better prognosis in pancreatic cancer patients14. Here, TRIM21 is linked to hepatocellular carcinoma.